Download Files:
Gemcitabine
$60 – $120
Products Details
Product Description
– Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].
Web ID
– HY-17026
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C9H11F2N3O4
Citations
– Acta Biochim Biophys Sin. 2021 Jan 12;gmaa177.|Adv Mater. 2021 May;33(18):e2100949.|Adv Sci (Weinh). 2023 Feb 19;e2206004.|Adv Sci (Weinh). 2023 Oct 22:e2302498.|Adv Sci (Weinh). 2023 Sep 3;e2303872.|Aging. 2020 Aug 28;12(16):16304-16325.|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.|Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.|Arch Toxicol. 2023 Dec;97(12):3209-3226.|ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.|Biochem Pharmacol. 2020 Jun 6;114085. |Biochem Pharmacol. 2021 Oct 18;193:114813.|Biol Pharm Bull. 2021 Dec 22.|Biomaterials. 16 September 2022.|Biomed Pharmacother. 2019 Sep;117:109185.|Biomed Pharmacother. 2022 Feb 11;148:112713.|Biomed Pharmacother. 2023 Aug 31;166:115389.|bioRxiv. 2023 Feb 28.|bioRxiv. 2023 Feb 7.|bioRxiv. 2023 Sep 5.|Breast Cancer Res Treat. 2023 May 19.|Cancer Lett. 2022 Jun 28;536:215651.|Cancer Lett. 2022 Nov 24;216023.|Cancer Med. 2019 Oct;8(13):5903-5915.|Cell Death Discov. 2021 May 1;7(1):89.|Cell Mol Life Sci. 2021 Oct 13.|Cell Prolif. 2021 Apr 1;e13038.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep Med. 2023 Oct 17;4(10):101234.|Cell Rep. 2022 Aug 16;40(7):111194.|Cell Res. 2020 Jul;30(7):574-589.|Chem Biol Interact. 2018 Jun 25;290:44-51.|Chem Eng J. 2023 Nov 17, 147466.|Chinese Chemical Letters. |Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.|Clin Transl Oncol. 2022 Jul 19.|DNA Cell Biol. 2021 Dec 13.|Elife. 2022 May 3;11:e69255.|Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. |Exp Cell Res. 2020 Dec 1;397(1):112335.|Front Oncol. 2021 Jul 13;11:704042.|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.|Hepatology. 2019 May;69(5):1995-2012. |Immun Inflamm Dis. 2023 Jun 14.|Inflamm Res. 2022 Oct 27.|Int Immunopharmacol. 2023 Jul 27;123:110709.|Int J Biol Sci. 2022 Jul 4;18(11):4301-4315.|Int J Biol Sci. 2022; 18(1):43-64.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Med Sci. 2022; 19(2): 286-298.|Invest New Drugs. 2022 Jan 4.|iScience. 6 September 2022, 105081.|J Biol Chem. 2017 Jun 2;292(22):9136-9149.|J Biol Chem. 2023 Jun 28;104984.|J Biomed Inform. 2023 May 15;104383.|J Control Release. 2023 Aug 4;361:161-177.|J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.|J Exp Clin Cancer Res. 2022 Oct 5;41(1):293.|J Exp Clin Cancer Res. 2023 May 4;42(1):111.|J Mater Chem B. 2023 Oct 11.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Nanobiotechnology. 2022 Jul 6;20(1):315.|J Transl Med. 2023 Nov 21;21(1):838.|Mol Cancer. 2023 Dec 4;22(1):195.|Mol Immunol. 2019 May;109:140-148. |Mol Pharm. 2021 Jun 2.|Molecules. 2022, 27(20), 6849.|Nature. 2019 Oct;574(7777):264-267. |Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622.|Onco Targets Ther. 2020 Sep 28;13:9543-9558.|Oncogene. 2023 Aug 31.|Oncol Lett. June 30, 2021.|Oncol Rep. 2022 Feb;47(2):33.|Oxid Med Cell Longev. 2022 Sep 29;2022:3243647.|Patent. US20210260092A1.|Patent. US20220362387A1.|Phytomedicine. 6 July 2022, 154323.|Phytother Res. 2022 Aug;36(8):3313-3324.|Redox Biol. 2021 Jan;38:101807.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Print. October 6th, 2022.|RSC Adv. 2022, 12, 28104-28112.|Sci Transl Med. 2021 Jan 20;13(577):eaba7401.|SLAS Discov. 2018 Aug;23(7):687-696. |Stem Cells Int. 2023 Jan 30.|Theranostics. 2021 Mar 24;11(12):5650-5674.|Transl Oncol. 2020 Sep;13(9):100804.|Transl Oncol. 2023 Oct 26:39:101803.|Transl Res. 2022.|Universidad de Granada. 2023 Mar 27.|University of Brescia. 2023 Feb 2.|View. 2023 Nov 15.|Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9.|Adv Sci (Weinh). 2022 May;9(15):e2105894.|Biomed J. 2020 Aug;43(4):368-374.|Br J Pharmacol. 2021 Jun;178(12):2496-2515.|Cancer Res. 2023 Jun 16;CAN-22-3346.|Chem Biol Interact. 2023 Nov 22:110816.|Heliyon. June 2022, e09643.|Int J Nanomedicine. 2023 Jul 19.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Pharmacol Exp Ther. 2018 Oct;367(1):20-27.|JCI Insight. 2022 Oct 13;e159419.|Molecules. 2023 Nov 12, 28(22), 7552.|Onco Targets Ther. 2019 Jun 12;12:4585-4593. |Oncol Lett. 2023 Sep 20.|Oncotarget. 2017 Oct 6;8(52):90185-90196. |PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Urol Oncol. 2021 Mar;39(3):194.e1-194.e7.
References
– [1]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.|[2]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206|[3]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80.|[4]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.
CAS Number
– 95058-81-4
Molecular Weight
– 263.20
Compound Purity
– 99.92
SMILES
– NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 250 mg/mL (ultrasonic)|Ethanol : 12.5 mg/mL (ultrasonic)|H2O : 6.25 mg/mL (ultrasonic;warming)
Target
– Apoptosis;Autophagy;DNA/RNA Synthesis;Nucleoside Antimetabolite/Analog
Pathway
– Apoptosis;Autophagy;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
